Top Page
Alcidion Group Limited
(Sydney:ALC)
Alcidion Group Limited (ALC) vs. iShares MSCI Australia ETF (EWA)
Alcidion Group Limited Business Overview & Revenue Model
Alcidion Group Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 40.79M | 40.79M | 37.06M | 40.40M | 34.35M | 25.88M |
| Gross Profit | 35.99M | 35.99M | 31.92M | 1.25M | 3.29M | 3.52M |
| EBITDA | 1.94M | 1.94M | -4.50M | -1.43M | -1.58M | -474.00K |
| Net Income | 1.65M | 1.65M | -8.42M | -3.62M | -4.41M | -2.24M |
Balance Sheet | ||||||
| Total Assets | 115.63M | 115.63M | 114.46M | 120.68M | 128.35M | 58.38M |
| Cash, Cash Equivalents and Short-Term Investments | 17.70M | 17.70M | 11.80M | 14.64M | 17.34M | 25.03M |
| Total Debt | 1.41M | 1.41M | 1.70M | 2.15M | 2.48M | 181.00K |
| Total Liabilities | 27.82M | 27.82M | 27.52M | 30.52M | 34.40M | 13.16M |
| Stockholders Equity | 87.80M | 87.80M | 86.94M | 90.17M | 93.95M | 45.22M |
Cash Flow | ||||||
| Free Cash Flow | 5.64M | 5.64M | -7.18M | -285.00K | 685.00K | 1.23M |
| Operating Cash Flow | 5.76M | 5.76M | -7.13M | 169.00K | 996.00K | 1.54M |
| Investing Cash Flow | -125.00K | -125.00K | -53.00K | -3.14M | -59.74M | -9.84M |
| Financing Cash Flow | -764.00K | -764.00K | 4.34M | -616.00K | 51.33M | 17.23M |
Alcidion Group Limited Technical Analysis
Alcidion Group Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | AU$126.24M | 78.33 | 1.89% | ― | 10.06% | ― | |
55 Neutral | AU$96.03M | ― | -8647.54% | ― | 25.98% | 21.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $71.67M | -11.82 | -12.35% | ― | 15.99% | 22.05% | |
48 Neutral | AU$58.12M | -9.39 | -13.83% | ― | 3.61% | -17.03% | |
40 Underperform | AU$145.04M | -6.25 | ― | ― | 21.56% | -24.08% | |
40 Underperform | AU$84.39M | -11.89 | ― | ― | ― | ― |
Alcidion Group Limited Corporate Events
Alcidion Group Limited announced the release of its Q1 FY26 Quarterly Cash Flow Report on 28 October 2025, accompanied by a live investor webcast featuring discussions on the quarter’s operational and commercial highlights. This announcement underscores Alcidion’s commitment to transparency and engagement with stakeholders, potentially influencing investor confidence and market positioning.
The most recent analyst rating on (AU:ALC) stock is a Buy with a A$0.13 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.
At its 2025 Annual General Meeting, Alcidion Group Limited announced that all resolutions were decided by poll, with the adoption of the Remuneration Report and the election of Andrew Way as a Director both carried. The approval of a 10% Placement Facility was withdrawn. These outcomes reflect Alcidion’s continued focus on strategic governance and operational decisions that align with its mission to enhance healthcare delivery.
The most recent analyst rating on (AU:ALC) stock is a Buy with a A$0.13 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.
Alcidion Group Limited, a leader in healthcare technology solutions, announced significant achievements at its 2025 Annual General Meeting. The company reported a record-setting fiscal year with total revenue of $40.8 million, a 10% increase from the previous year, and secured $73.8 million in new contracts. Notably, Alcidion’s Miya Precision platform continues to gain traction, highlighted by a landmark $39 million contract with North Cumbria NHS Trust. The company’s financial health is robust, with no debt and a cash reserve of $17.7 million, positioning it well for further growth and innovation in the healthcare sector.
The most recent analyst rating on (AU:ALC) stock is a Buy with a A$0.13 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.
Alcidion Group Limited announced the withdrawal of ‘Resolution 3 – Approval of 10% Placement Facility’ from its upcoming Annual General Meeting agenda. This decision follows shareholder feedback and the company’s current lack of intention to use the additional placement capacity. The withdrawal does not affect the validity of proxy votes for other resolutions, which will proceed as planned. This move reflects Alcidion’s responsiveness to shareholder input and its current strategic focus, potentially impacting its capital management strategies.
The most recent analyst rating on (AU:ALC) stock is a Buy with a A$0.13 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.
Alcidion Group Limited has announced an expansion of its contract with North Cumbria Integrated Care NHS Foundation Trust to include MediViewer, an Electronic Document Management System, into its Miya Precision Electronic Patient Record solution. This integration will provide seamless access to scanned and historical documents, enhancing clinical workflows and digital maturity. The contract, valued at approximately $6.8 million over 9.4 years, aligns with Alcidion’s strategy to support the digitization of healthcare workflows and improve patient care efficiency. The implementation of MediViewer is expected to drive regional convergence and efficiency, laying the groundwork for future adoption of emerging technologies like AI and predictive analytics.
The most recent analyst rating on (AU:ALC) stock is a Buy with a A$0.13 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.
Alcidion Group Limited announced its participation in an investor roadshow in Sydney, aiming to engage with investors and present its growth strategy following the FY25 results. This initiative reflects Alcidion’s commitment to expanding its market presence and underscores its strategic focus on leveraging technology to transform healthcare delivery.
The most recent analyst rating on (AU:ALC) stock is a Buy with a A$0.13 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.
Alcidion Group Limited has released its 2025 Corporate Governance Statement, detailing its adherence to the ASX Corporate Governance Council’s Principles and Recommendations. The company emphasizes the importance of strong corporate governance in ensuring future success, adding value to stakeholders, and enhancing investor confidence. The statement outlines the roles and responsibilities of the Board and management, the process for appointing directors, and the company’s commitment to diversity and inclusion. Alcidion also highlights its efforts towards gender equality and the implementation of a Reflect Reconciliation Action Plan and a Diversity and Inclusion Strategy for 2024-2026. These initiatives are aimed at fostering a diverse and inclusive workplace, which is seen as crucial for innovation and understanding customer needs.
The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.
Alcidion Group Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement confirms that the company has adhered to the ASX Corporate Governance Council’s principles and recommendations, with disclosures on board responsibilities, director appointments, and executive agreements, thereby ensuring transparency and accountability in its governance practices.
The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.
Alcidion Group Limited has released its FY25 results, highlighting the company’s continued focus on leveraging technology to improve healthcare delivery. The announcement underscores the company’s commitment to providing advanced digital solutions that enhance healthcare operations, although it cautions stakeholders about the inherent uncertainties and risks associated with forward-looking statements and financial projections.
The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.
Alcidion Group Limited reported a transformative financial year in FY25, achieving a record underlying EBITDA of $5.1 million and a 10% increase in revenue to $40.8 million. The company secured significant new contracts, including a major Electronic Patient Record deployment with North Cumbria NHS Trust, validating its dual market position. With a strong cash balance and no debt, Alcidion is poised for further growth in FY26, leveraging its Miya platform to expand into new markets and enhance patient flow solutions.
The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.
Alcidion Group Limited has released its Annual Report for 2025, emphasizing its commitment to reconciliation and fostering understanding between Aboriginal and Torres Strait Islander peoples and the wider community. The company acknowledges the traditional custodians of the land and aims to contribute to an inclusive and prosperous Australia, highlighting its dedication to cultural respect and celebration.
The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.
Alcidion Group Limited reported a significant turnaround in its financial performance for the fiscal year ending June 2025, achieving a profit of $1.654 million compared to a loss in the previous year. This improvement was driven by a 10% increase in revenue due to new sales in ANZ and the UK, a reduction in staff costs following a restructuring, and an increased income tax benefit. The company also established a new subsidiary in Canada, although it did not contribute to the year’s profit.
The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.
Alcidion Group Limited announced the cessation of 449,603 performance rights due to unmet conditions, impacting its issued capital. This development may influence the company’s financial structuring and stakeholder interests, as it reflects on the company’s performance metrics and strategic planning.
The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.
Alcidion Group Limited has announced a revision to its Securities Trading Policy in compliance with ASX Listing Rule 12.10. This update is part of the company’s ongoing efforts to maintain robust corporate governance practices. The revised policy is available on Alcidion’s website, reflecting the company’s commitment to transparency and regulatory compliance, which is crucial for its stakeholders and market positioning.
The most recent analyst rating on (AU:ALC) stock is a Buy with a A$0.09 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.